1Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq
*Corresponding Author: Firas A. Hassan, Alaa Hussein j Al-qaisi, Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq, Email: firas.hassan2014@yahoo.com
Online published on 23 December, 2019.
Ovarian cancer is the most deadly gynecologic malignancy. It's well-known as the silent killer since in most cases there are no warning symptoms and signs until the spread of cancer to other organs. Therefore, the aim of current study was to measure the levels of enzymes such as α-Amylase, Lactate Dehydrogenase A, 5-Nucleotidase and 17-Beta-Hydroxysteroid Dehydrogenase type 14 were measured in the blood stream of ovarian cancer patients and healthy groups with different age ranges in try to find new biomarker that could be used a potentially assistance in early diagnosis of ovarian cancer.
Blood samples were collected from 80 women at local hospitals in Baghdad. The subjects were divided into 2 groups depending on their age. Group 1 (25 females) aged between (20–40) years with ovarian cancer and 15 healthy women as controls. On the other hand, group 2 aged between (40–60) years and included 25 patients with ovarian cancer and 15 healthy women as controls. Enzymes levels (α-Amylase, Lactate Dehydrogenase A, 5-Nucleotidase and Human17-Beta-Hydroxysteroid Dehydrogenase type 14) were measured for both groups.
Data from current study showed that there was an increase in all measured enzymes concentrations in the serum of patients with ovarian cancer in comparison with their controls for both age groups with (P-Value = 0.0001).
Elevated serum levels of the enzymes α-Amylase, Lactate Dehydrogenase A, 5-Nucleotidase and 17-Beta-Hydroxysteroid Dehydrogenase type 14 level would be employed as potentially new biomarkers that can assist in early diagnosis of ovarian cancer.
Ovarian cancer, Oxidative stress, Antioxidant, Enzymes, Biomarkers
